Across TCGA pan-cancer cohorts, MIR890 Mutation is linked to patient survival in 3 of 34 cancer types, making it the most broadly survival-associated MIR890 data layer compared with 2 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MIR890 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR890 expression acts as an unfavorable survival marker.

BLCA, LUAD, and LUSC are the cancer types where MIR890 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.063	0.710	<.001	48	view →
LUAD	DFS	Median	All	0.206	0.791	.001	21	view →
LUSC	OS	Median	II,III,IV	0.279	0.732	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MIR890 tumor-vs-normal RNA expression · all MIR890 data types